Mineralys Therapeutics Advances lorundrostat Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MLYS?
"We continue to make strong progress advancing lorundrostat toward potential approval, moving closer towards our goal of delivering what we believe has the potential to be a best-in-class aldosterone synthase inhibitor for patients with uncontrolled or resistant hypertension," said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. "The FDA's acceptance of our NDA in the first quarter marks a significant milestone for Mineralys. We continue to advance pre-commercial activities to support a successful launch of lorundrostat while maintaining strategic flexibility."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLYS
Wall Street analysts forecast MLYS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.540
Low
46.00
Averages
52.60
High
56.00
Current: 29.540
Low
46.00
Averages
52.60
High
56.00
About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mineralys Therapeutics Q1 2026 Earnings Call Highlights
- FDA Acceptance Milestone: Mineralys Therapeutics successfully received FDA acceptance for the NDA of lorundrostat in Q1 2026, with a PDUFA target date set for December 22, 2026, establishing a crucial foundation for future commercialization efforts.
- Stable Financial Position: As of March 31, 2026, the company reported cash and cash equivalents totaling $646.1 million, indicating that these resources are expected to support operations into 2028, reflecting strong financial health.
- Decline in R&D Expenses: R&D expenses for Q1 2026 were $24.4 million, significantly down from $37.9 million in Q1 2025, showcasing a strategic shift in spending during the clinical trial phase.
- Market Access Strategy: Management emphasized a focus on market access for fourth-line hypertension patients, ensuring “parity access” with competitors to enhance the market competitiveness of lorundrostat.
See More
Mineralys Grants Stock Options and RSUs to New Employees
- Stock Option Grants: On May 4, 2026, Mineralys Therapeutics granted a total of 29,760 stock options to two new non-executive employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Restricted Stock Units: The company also awarded 22,320 restricted stock units that will vest over four years, with the first vesting occurring on the anniversary of the grant date, reflecting the company's long-term commitment to new employees and promoting team stability.
- Vesting Mechanism: The stock options will vest gradually over four years, with 25% vesting in the first year and 1/48 vesting monthly thereafter, ensuring that employees contribute continuously during their tenure, which enhances their sense of belonging.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's adherence to regulations and transparency in attracting new employees, which further boosts investor confidence in the company.
See More
Mineralys CEO Sells 75,000 Shares Amid Market Fluctuations
- Executive Stock Sale: Jon Congleton, CEO of Mineralys Therapeutics, sold 75,000 shares on March 31 through multiple open-market transactions valued at approximately $1.97 million, indicating active trading behavior in the company's stock.
- Holding Proportion Change: The sale impacted 9.61% of Congleton's direct holdings, leaving him with 705,051 shares, which represents about 58.6% of his position from August 2023, suggesting he still retains confidence in the company.
- Trading Plan Context: The stock sale was executed under Congleton's Rule 10b5-1 trading plan adopted in December 2025, which is designed to avoid legal issues related to insider trading, reflecting his cautious approach to compliance.
- Market Reaction and Risks: While Congleton's sale may raise market concerns, Mineralys stock has significantly dropped from its 52-week high of $47.65 last November in 2026, prompting investors to carefully assess the impact of the company's clinical trial results on future stock performance.
See More
Dell and Super Group See Surge in Options Trading Volume
- Dell Options Volume: Dell Technologies saw options trading volume of 56,231 contracts, representing approximately 5.6 million shares, which is about 59.2% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High-Frequency Contracts: Notably, the $210 strike put option expiring March 19, 2027, has seen 5,000 contracts traded today, equating to approximately 500,000 shares, suggesting an increasing bearish sentiment among investors regarding Dell's stock price.
- Super Group Options Activity: Super Group Ltd recorded options trading volume of 12,084 contracts, representing around 1.2 million shares, which constitutes about 58.1% of its average daily trading volume over the past month, reflecting sustained market interest in the company.
- Bullish Call Options: Within Super Group, the $8.75 strike call option expiring April 17, 2026, has traded 6,499 contracts today, representing approximately 649,900 shares, indicating a bullish outlook among investors for the company's future stock performance.
See More
ETF Analysis: FTLS Implied Upside of 21.41%
- FTLS Potential Upside: The First Trust Long/Short Equity ETF (FTLS) has an implied analyst target price of $84.44 per unit, while trading at $69.55, indicating a potential upside of 21.41%, reflecting investor optimism about the ETF's future performance.
- MLYS Stock Analysis: Mineralys Therapeutics Inc (MLYS) trades at $23.28, with an analyst target price of $50.00, suggesting a potential upside of 114.78%, which indicates strong market confidence in its future growth prospects.
- Q Company Outlook: Qnity Electronics, Inc. (Q) has a current share price of $111.94, with an analyst target price of $233.67, showing an upside of 108.74%, highlighting analysts' very optimistic expectations for its future performance.
- LIF Investment Potential: Life360 Inc (LIF) is currently priced at $39.27, with an analyst target price of $75.97, representing a potential upside of 93.45%, further emphasizing the market's positive outlook on the company.
See More
Mineralys Therapeutics Q4 2025 Earnings Call Highlights
- FDA NDA Acceptance: CEO Jon Congleton highlighted the FDA's acceptance of the NDA for lorundrostat, with a PDUFA target action date of December 22, 2026, marking a significant milestone that positions the company for rapid entry into the U.S. hypertension market.
- Improved Financial Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $656.6 million, a substantial increase from $198.2 million in 2024, indicating sufficient funding for planned clinical trials and regulatory activities.
- Decrease in R&D Expenses: R&D expenses for 2025 were $132 million, down from $168.6 million in 2024, primarily due to the completion of the lorundrostat pivotal program, allowing the company to focus resources on market launch and commercialization strategies.
- Market Opportunity Outlook: Management reiterated the market potential for lorundrostat in patients with resistant hypertension, expecting rapid uptake post-approval while also evaluating further indications and potential partnerships for international expansion.
See More
Mineralys Therapeutics Q1 2026 Earnings Call Highlights
- FDA Acceptance Milestone: Mineralys Therapeutics successfully received FDA acceptance for the NDA of lorundrostat in Q1 2026, with a PDUFA target date set for December 22, 2026, establishing a crucial foundation for future commercialization efforts.
- Stable Financial Position: As of March 31, 2026, the company reported cash and cash equivalents totaling $646.1 million, indicating that these resources are expected to support operations into 2028, reflecting strong financial health.
- Decline in R&D Expenses: R&D expenses for Q1 2026 were $24.4 million, significantly down from $37.9 million in Q1 2025, showcasing a strategic shift in spending during the clinical trial phase.
- Market Access Strategy: Management emphasized a focus on market access for fourth-line hypertension patients, ensuring “parity access” with competitors to enhance the market competitiveness of lorundrostat.
See More
Mineralys Grants Stock Options and RSUs to New Employees
- Stock Option Grants: On May 4, 2026, Mineralys Therapeutics granted a total of 29,760 stock options to two new non-executive employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Restricted Stock Units: The company also awarded 22,320 restricted stock units that will vest over four years, with the first vesting occurring on the anniversary of the grant date, reflecting the company's long-term commitment to new employees and promoting team stability.
- Vesting Mechanism: The stock options will vest gradually over four years, with 25% vesting in the first year and 1/48 vesting monthly thereafter, ensuring that employees contribute continuously during their tenure, which enhances their sense of belonging.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's adherence to regulations and transparency in attracting new employees, which further boosts investor confidence in the company.
See More
Mineralys CEO Sells 75,000 Shares Amid Market Fluctuations
- Executive Stock Sale: Jon Congleton, CEO of Mineralys Therapeutics, sold 75,000 shares on March 31 through multiple open-market transactions valued at approximately $1.97 million, indicating active trading behavior in the company's stock.
- Holding Proportion Change: The sale impacted 9.61% of Congleton's direct holdings, leaving him with 705,051 shares, which represents about 58.6% of his position from August 2023, suggesting he still retains confidence in the company.
- Trading Plan Context: The stock sale was executed under Congleton's Rule 10b5-1 trading plan adopted in December 2025, which is designed to avoid legal issues related to insider trading, reflecting his cautious approach to compliance.
- Market Reaction and Risks: While Congleton's sale may raise market concerns, Mineralys stock has significantly dropped from its 52-week high of $47.65 last November in 2026, prompting investors to carefully assess the impact of the company's clinical trial results on future stock performance.
See More
Dell and Super Group See Surge in Options Trading Volume
- Dell Options Volume: Dell Technologies saw options trading volume of 56,231 contracts, representing approximately 5.6 million shares, which is about 59.2% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High-Frequency Contracts: Notably, the $210 strike put option expiring March 19, 2027, has seen 5,000 contracts traded today, equating to approximately 500,000 shares, suggesting an increasing bearish sentiment among investors regarding Dell's stock price.
- Super Group Options Activity: Super Group Ltd recorded options trading volume of 12,084 contracts, representing around 1.2 million shares, which constitutes about 58.1% of its average daily trading volume over the past month, reflecting sustained market interest in the company.
- Bullish Call Options: Within Super Group, the $8.75 strike call option expiring April 17, 2026, has traded 6,499 contracts today, representing approximately 649,900 shares, indicating a bullish outlook among investors for the company's future stock performance.
See More
ETF Analysis: FTLS Implied Upside of 21.41%
- FTLS Potential Upside: The First Trust Long/Short Equity ETF (FTLS) has an implied analyst target price of $84.44 per unit, while trading at $69.55, indicating a potential upside of 21.41%, reflecting investor optimism about the ETF's future performance.
- MLYS Stock Analysis: Mineralys Therapeutics Inc (MLYS) trades at $23.28, with an analyst target price of $50.00, suggesting a potential upside of 114.78%, which indicates strong market confidence in its future growth prospects.
- Q Company Outlook: Qnity Electronics, Inc. (Q) has a current share price of $111.94, with an analyst target price of $233.67, showing an upside of 108.74%, highlighting analysts' very optimistic expectations for its future performance.
- LIF Investment Potential: Life360 Inc (LIF) is currently priced at $39.27, with an analyst target price of $75.97, representing a potential upside of 93.45%, further emphasizing the market's positive outlook on the company.
See More
Mineralys Therapeutics Q4 2025 Earnings Call Highlights
- FDA NDA Acceptance: CEO Jon Congleton highlighted the FDA's acceptance of the NDA for lorundrostat, with a PDUFA target action date of December 22, 2026, marking a significant milestone that positions the company for rapid entry into the U.S. hypertension market.
- Improved Financial Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $656.6 million, a substantial increase from $198.2 million in 2024, indicating sufficient funding for planned clinical trials and regulatory activities.
- Decrease in R&D Expenses: R&D expenses for 2025 were $132 million, down from $168.6 million in 2024, primarily due to the completion of the lorundrostat pivotal program, allowing the company to focus resources on market launch and commercialization strategies.
- Market Opportunity Outlook: Management reiterated the market potential for lorundrostat in patients with resistant hypertension, expecting rapid uptake post-approval while also evaluating further indications and potential partnerships for international expansion.
See More
